On Jan 09, major Wall Street analysts update their ratings for $Sana Biotechnology (SANA.US)$, with price targets ranging from $7 to $11.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and maintains the target price at $9.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and maintains the target price at $7.
TD Cowen analyst Marc Frahm upgrades to a buy rating.
H.C. Wainwright analyst Emily Bodnar maintains with a buy rating, and adjusts the target price from $8 to $11.
JMP Securities analyst Reni Benjamin maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Sana Biotechnology (SANA.US)$'s main analysts recently are as follows:
Political and rate uncertainty remains a concern, yet the health of the Biopharma sector is perceived as significantly better than its 2022 lows. Analysts continue to favor stories about late-stage clinical trials or early product launches. Additionally, Phase 1 clinical programs that offer derisking data and near-term catalysts are becoming increasingly important focal points for investors.
Positive data from Sana Biotechnology indicate that Hypoimmune modified cadaver islet cells sustained immune evasion and C-peptide production in a type 1 diabetes patient without immunosuppression. This data establishes a proof of concept for Hypoimmune's immune evasion properties and significantly derisks applications in type 1 diabetes and other fields. Although considerable work remains in terms of commercialization, the company is considered to have a notably changed risk profile.
Here are the latest investment ratings and price targets for $Sana Biotechnology (SANA.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
